Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine

Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated... Clin Pharmacokinet (2018) 57:729–737 https://doi.org/10.1007/s40262-017-0591-8 OR IGINAL RESEARCH ARTIC L E Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine 1,2 1,2,5 3,4 • • • Maxim Kuzin Georgios Schoretsanitis Ekkehard Haen 3,4 6,7 1,2 • • • Benedikt Stegmann Christoph Hiemke Gerhard Gru ¨ nder 1,2,8 Michael Paulzen Published online: 2 September 2017 Springer International Publishing AG 2017 Abstract venlafaxine, O-desmethylvenlafaxine and active moiety Background and Objective An increasing trend in pre- (venlafaxine ? O-desmethylvenlafaxine), as well as dose- scribing proton pump inhibitors (PPIs) inevitably increases adjusted plasma concentrations, were compared using non- the risk of unwanted drug–drug interactions (DDIs). The parametrical tests. aim of this study was to uncover pharmacokinetic inter- Results Daily doses of venlafaxine did not differ between actions between two PPIs—omeprazole and pantopra- groups (p = 0.949). The Mann–Whitney U test showed sig- zole—and venlafaxine. nificantly higher plasma concentrations of active moiety, as Methods A therapeutic drug monitoring database con- well as venlafaxine and O-desmethylvenlafaxine, in both PPI tained plasma concentrations of venlafaxine and its active groups [p = 0.023, p = 0.011, p = 0.026, ?29% active metabolite O-desmethylvenlafaxine. We considered three moiety, ?27% venlafaxine, ?36% http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Pharmacokinetics Springer Journals

Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine

Download PDF
9 pages

Loading next page...
 
/lp/springer_journal/effects-of-the-proton-pump-inhibitors-omeprazole-and-pantoprazole-on-HIfKxvRLE4
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG
Subject
Medicine & Public Health; Pharmacotherapy; Pharmacology/Toxicology; Internal Medicine
ISSN
0312-5963
eISSN
1179-1926
DOI
10.1007/s40262-017-0591-8
Publisher site
See Article on Publisher Site

Abstract

Clin Pharmacokinet (2018) 57:729–737 https://doi.org/10.1007/s40262-017-0591-8 OR IGINAL RESEARCH ARTIC L E Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine 1,2 1,2,5 3,4 • • • Maxim Kuzin Georgios Schoretsanitis Ekkehard Haen 3,4 6,7 1,2 • • • Benedikt Stegmann Christoph Hiemke Gerhard Gru ¨ nder 1,2,8 Michael Paulzen Published online: 2 September 2017 Springer International Publishing AG 2017 Abstract venlafaxine, O-desmethylvenlafaxine and active moiety Background and Objective An increasing trend in pre- (venlafaxine ? O-desmethylvenlafaxine), as well as dose- scribing proton pump inhibitors (PPIs) inevitably increases adjusted plasma concentrations, were compared using non- the risk of unwanted drug–drug interactions (DDIs). The parametrical tests. aim of this study was to uncover pharmacokinetic inter- Results Daily doses of venlafaxine did not differ between actions between two PPIs—omeprazole and pantopra- groups (p = 0.949). The Mann–Whitney U test showed sig- zole—and venlafaxine. nificantly higher plasma concentrations of active moiety, as Methods A therapeutic drug monitoring database con- well as venlafaxine and O-desmethylvenlafaxine, in both PPI tained plasma concentrations of venlafaxine and its active groups [p = 0.023, p = 0.011, p = 0.026, ?29% active metabolite O-desmethylvenlafaxine. We considered three moiety, ?27% venlafaxine, ?36%

Journal

Clinical Pharmacokinetics – Springer Journals

Published: Sep 2, 2017

References

  • Individualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug)—study protocol for a pragmatic randomized controlled trial
    Stingl, JC; Kaumanns, KL; Claus, K; Lehmann, ML; Kastenmuller, K; Bleckwenn, M
  • Drug interactions in the elderly. How multiple drug use increases risk exponentially
    Cadieux, RJ
  • Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients—thinking of clinically relevant CYP2D6 interactions
    Paulzen, M; Haen, E; Gründer, G; Lammertz, SE; Stegmann, B; Schruers, KR
  • Pharmacokinetic patterns of risperidone-associated adverse drug reactions
    Schoretsanitis, G; Stegmann, B; Hiemke, C; Gründer, G; Schruers, KR; Walther, S
  • Risperidone-induced extrapyramidal side effects: is the need for anticholinergics the consequence of high plasma concentrations?
    Schoretsanitis, G; Haen, E; Hiemke, C; Gründer, G; Stegmann, B; Schruers, KR
  • A Canadian Primary Care Sentinel Surveillance Network study evaluating antidepressant prescribing in Canada from 2006 to 2012
    Morkem, R; Barber, D; Williamson, T; Patten, SB
  • Trends in prescription drug use among adults in the United States from 1999–2012
    Kantor, ED; Rehm, CD; Haas, JS; Chan, AT; Giovannucci, EL
  • Arzneiverordnungs-report 2015: Berlin
    Schwabe, U; Paffrath, D
  • Polypharmacy patterns: unravelling systematic associations between prescribed medications
    Calderon-Larranaga, A; Gimeno-Feliu, LA; Gonzalez-Rubio, F; Poblador-Plou, B; Lairla-San Jose, M; Abad-Diez, JM
  • Effect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram, and sertraline
    Gjestad, C; Westin, AA; Skogvoll, E; Spigset, O
  • Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers
    Rocha, A; Coelho, EB; Sampaio, SA; Lanchote, VL
  • Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients
    Bondolfi, G; Morel, F; Crettol, S; Rachid, F; Baumann, P; Eap, CB
  • O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants
    Fogelman, SM; Schmider, J; Venkatakrishnan, K; Moltke, LL; Harmatz, JS; Shader, RI
  • An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects
    Patroneva, A; Connolly, SM; Fatato, P; Pedersen, R; Jiang, Q; Paul, J
  • The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults
    Nichols, AI; Fatato, P; Shenouda, M; Paul, J; Isler, JA; Pedersen, RD
  • The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel
    Ogilvie, BW; Yerino, P; Kazmi, F; Buckley, DB; Rostami-Hodjegan, A; Paris, BL
  • Therapeutic drug monitoring in pharmacovigilance and pharmacotherapy safety
    Haen, E
  • AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011
    Hiemke, C; Baumann, P; Bergemann, N; Conca, A; Dietmaier, O; Egberts, K
  • CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine
    Shams, ME; Arneth, B; Hiemke, C; Dragicevic, A; Müller, MJ; Kaiser, R
  • Drug interaction between clopidogrel and proton pump inhibitors
    Liu, TJ; Jackevicius, CA
  • Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture
    Curi-Pedrosa, R; Daujat, M; Pichard, L; Ourlin, JC; Clair, P; Gervot, L
  • Specific and dose-dependent enzyme induction by omeprazole in human beings
    Rost, KL; Brosicke, H; Heinemeyer, G; Roots, I
  • Omeprazole reduces clozapine plasma concentrations. A case report
    Frick, A; Kopitz, J; Bergemann, N
  • Induction of cytochrome P4501A by smoking or omeprazole in comparison with UDP-glucuronosyltransferase in biopsies of human duodenal mucosa
    Buchthal, J; Grund, KE; Buchmann, A; Schrenk, D; Beaune, P; Bock, KW
  • Retrospective evaluation of the effect of omeprazole on clozapine metabolism
    Mookhoek, EJ; Loonen, AJ
  • Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases
    Karlsson, L; Zackrisson, AL; Josefsson, M; Carlsson, B; Green, H; Kugelberg, FC
  • Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite
    Klamerus, KJ; Maloney, K; Rudolph, RL; Sisenwine, SF; Jusko, WJ; Chiang, ST
  • Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities
    Li, XQ; Andersson, TB; Ahlstrom, M; Weidolf, L
  • CYP2C19 polymorphism and proton pump inhibitors
    Klotz, U; Schwab, M; Treiber, G
  • Association between the CYP2C9 polymorphism and the drug metabolism phenotype
    Topic, E; Stefanovic, M; Samardzija, M
  • CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers
    Gawronska-Szklarz, B; Adamiak-Giera, U; Wyska, E; Kurzawski, M; Gornik, W; Kaldonska, M
  • Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis
    Ichikawa, H; Sugimoto, M; Sugimoto, K; Andoh, A; Furuta, T
  • Omeprazole and CYP2C19 polymorphism: effects of long-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders
    Sagar, M; Bertilsson, L; Stridsberg, M; Kjellin, A; Mardh, S; Seensalu, R
  • Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian population
    Payan, M; Rouini, MR; Tajik, N; Ghahremani, MH; Tahvilian, R
  • Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors
    Deshpande, N; Sharanya, V; Ravi Kanth, VV; Murthy, HVV; Sasikala, M; Banerjee, R
  • Prediction of antidepressant response to venlafaxine by a combination of early response assessment and therapeutic drug monitoring
    Stamm, TJ; Becker, D; Sondergeld, LM; Wiethoff, K; Hiemke, C; O’Malley, G
  • Serum level of venlafaxine is associated with better memory in psychotic disorders
    Steen, NE; Aas, M; Simonsen, C; Dieset, I; Tesli, M; Nerhus, M
  • Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder
    Lobello, KW; Preskorn, SH; Guico-Pabia, CJ; Jiang, Q; Paul, J; Nichols, AI
  • Antidepressant exposure as a predictor of clinical outcomes in the treatment of resistant depression in adolescents (TORDIA) study
    Sakolsky, DJ; Perel, JM; Emslie, GJ; Clarke, GN; Wagner, KD; Vitiello, B
  • Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein
    Pauli-Magnus, C; Rekersbrink, S; Klotz, U; Fromm, MF
  • The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs
    Hendset, M; Haslemo, T; Rudberg, I; Refsum, H; Molden, E
  • Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine
    Bachmeier, CJ; Beaulieu-Abdelahad, D; Ganey, NJ; Mullan, MJ; Levin, GM
  • Effect of proton pump inhibitors on gastric juice volume, gastric pH and gastric intramucosal pH in critically ill patients: a randomized, double-blind, placebo-controlled study
    Gursoy, O; Memis, D; Sut, N
  • Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone. A pharmacokinetics-based hypothesis
    Paulzen, M; Haen, E; Stegmann, B; Hiemke, C; Gründer, G; Lammertz, SE
  • A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects
    Hassan-Alin, M; Andersson, T; Niazi, M; Rohss, K
  • Rabeprazole: a pharmacologic and clinical review for acid-related disorders
    Dadabhai, A; Friedenberg, FK
  • Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics
    Klamerus, KJ; Parker, VD; Rudolph, RL; Derivan, AT; Chiang, ST
  • The effect of age, sex, smoking and co-medication on serum levels of venlafaxine and O-desmethylvenlafaxine under naturalistic conditions
    Unterecker, S; Hiemke, C; Greiner, C; Haen, E; Jabs, B; Deckert, J
  • Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting
    Reis, M; Lundmark, J; Bjork, H; Bengtsson, F